Skip to content

Randomized controlled trial of a smartphone application for suicide prevention (MYPLAN Japanese version)

A randomized controlled trial evaluating the effectiveness of the MYPLAN Japanese version smartphone application for suicide prevention among patients with suicidal ideation - MYPLAN-J RCT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059731
Enrollment
50
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatic disorders, with suicidal ideation

Interventions

Standard psychiatric treatment with MYPLAN Japanese version smartphone application, used over 15 minutes per day from enrollment. Standard psychiatric treatment
MYPLAN app provided after 8 weeks.

Sponsors

Sapporo Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Sixteen years of age or older 2. Suicidal ideation (PHQ-9 Item 9 score of 1 or higher.) 3. Owns a smartphone and able to install the app 4. Understands Japanese 5. Provides written informed consent

Exclusion criteria

Exclusion criteria: 1. No smartphone / unable to install app 2. Cannot understand Japanese 3. Current psychotic symptoms 4. Cognitive impairment 5. Considered unsuitable by treating psychiatrist 6. Other investigator-determined reasons

Design outcomes

Primary

MeasureTime frame
Incidence of suicide attempt or self-harm within 8 weeks after enrollment

Secondary

MeasureTime frame
PHQ-9 (depression) SF-8 (quality of life) Original questionairs (ability to cope with suicidal ideation, app usability and satisfaction)

Countries

Japan

Contacts

Public ContactKenji Narita

Sapporo Medical University Hospital Department of Neuropsychiatry

knarita@sapmed.ac.jp+81-11-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026